For radiation oncologists, neurosurgeons, hospital administrators, and medical technology investors, the treatment of brain tumors, arteriovenous malformations (AVMs), and selected extracranial oligometastases has been transformed by stereotactic radiosurgery (SRS). Traditional open brain surgery carries significant risks: infection, bleeding, neurological damage, lengthy recovery (weeks to months), and inoperability for deep-seated or multiple lesions. Conventional fractionated radiation therapy (30+ sessions over 6 weeks) is non-invasive but delivers lower dose per fraction, requiring more treatments and reducing patient convenience. Stereotactic Radiosurgery (SRS)—a non-incisional, high-precision radiation therapy technique using a stereotactic reference system and image guidance—delivers a highly focused, ablative dose to a clearly defined target (classically in the head) with millimeter-level accuracy. SRS is commonly used for single-fraction treatment; fractionated stereotactic radiotherapy (2–5 fractions) follows the same accuracy requirements. This industry deep-dive analysis, based on the latest report by Global Leading Market Research Publisher QYResearch, integrates Q4 2025–Q2 2026 market data, real-world clinical deployment case studies, and exclusive insights on Gamma Knife vs. Linear Accelerator (Linac) vs. Proton Beam Therapy technologies. It delivers a strategic roadmap for healthcare executives and investors targeting the rapidly expanding US$5.92 billion SRS market.
Market Size and Growth Trajectory (QYResearch Data)
According to the just-released report *“Stereotactic Radiosurgery (SRS) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*, the global market for stereotactic radiosurgery systems was valued at approximately US$ 3,527 million in 2025 and is projected to reach US$ 5,921 million by 2032, representing a compound annual growth rate (CAGR) of 7.6% from 2026 to 2032. Global sales reached approximately 2,528 units in 2025, with an average global market price of approximately US$ 1.4 million per unit. Gross profit margins range from approximately 30% to 45% , with premium vendors (Elekta, Varian, Accuray) achieving higher margins (40–45%) through software and service bundling.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5686098/stereotactic-radiosurgery–srs
Product Definition and Technology Classification
Stereotactic Radiosurgery (SRS) is a non-invasive, high-precision radiation therapy technique that delivers a single, high ablative dose (typically 15–24 Gy) to a small, clearly defined target (brain metastases, benign tumors, AVMs, trigeminal neuralgia, and selected extracranial oligometastases via SBRT). Key technical characteristics vary by radiation delivery platform.
The market is segmented by technology (radiation source and delivery method):
- Gamma Knife (2025 share: 35%): Dedicated SRS system using 192–201 stationary cobalt-60 (Co-60) sources focused on a single isocenter (hemispherical collimation). Advantages: sub-millimeter accuracy (0.15–0.3 mm), steep dose fall-off, no moving parts during treatment (high reliability). Disadvantages: cobalt-60 decays (5.27-year half-life, requires source replacement every 5–7 years, US$200,000–400,000 per replacement), limited to cranial indications. Market leader: Elekta (Leksell Gamma Knife). Slower growth (CAGR 6.5%) as Linac-based SRS expands.
- Linear Accelerator (Linac) (55%): Conventional medical linear accelerator (6–10 MV photons) adapted for SRS/SBRT using cone-based collimation, micro-multileaf collimators (MLC, 2.5–5 mm leaf width), or dedicated SRS attachments. Advantages: multi-purpose (conventional radiotherapy, IMRT, VMAT, SRS, SBRT, and stereotactic body radiation therapy), no source decay, can treat cranial and extracranial (spine, lung, liver, prostate) targets. Fastest-growing segment (CAGR 8.5%) as Linac-based SRS becomes standard capability. Market leaders: Varian (Halcyon, TrueBeam, Edge), Elekta (Versa HD, Unity MR-Linac), Accuray (Radixact, TomoTherapy).
- Proton Beam Therapy (10%): Proton beam SRS uses the Bragg peak (sharp dose fall-off beyond target) to minimize dose to normal brain. Advantages: superior dose distribution for pediatric brain tumors, skull base tumors, and re-irradiation. Disadvantages: very high capital cost (US$20–50 million per system), large footprint (bunker size), limited availability. Slowest-growing segment (CAGR 5.5%) due to cost constraints.
Industry Segmentation by Application (Treatment Site)
- Brain Stereotactic Radiosurgery (2025 share: 70%): Brain metastases (40–50% of SRS procedures), benign tumors (meningioma, vestibular schwannoma, pituitary adenoma), arteriovenous malformations (AVMs), trigeminal neuralgia, and functional indications. A January 2026 case study from a large US academic medical center (1,500 SRS procedures annually) using Gamma Knife for brain metastases (4–20 lesions per patient, 2–5 treatments per patient) achieved 90% local control at 12 months (vs. 95% for surgical resection) with zero mortality (vs. 2–3% for surgery) and same-day discharge. SRS replaced surgical resection for 80% of brain metastasis patients, reducing hospital stay from 5 days to 1 day, saving US$12,000 per patient in direct costs.
- Stereotactic Body Radiation Therapy (SBRT) (30%): Extracranial SRS (spine, lung, liver, prostate, pancreas, kidney, adrenal) requiring motion management (respiratory gating, abdominal compression, fiducial tracking) and immobilization. A February 2026 deployment from a European cancer center (2,000 SBRT procedures annually) using Linac-based SBRT (flattening filter-free, 10 MV, 10–20 Gy × 3–5 fractions) for early-stage lung cancer (medically inoperable) achieved 3-year local control of 90% (comparable to surgical resection) with zero treatment-related mortality (vs. 1–3% for surgery). SBRT replaced surgery for 60% of early-stage lung cancer patients.
Key Industry Development Characteristics (2025–2026)
Regional Market Structure: North America is the largest market (approximately 45% share), driven by high cancer incidence (brain metastases common in lung cancer, breast cancer, melanoma), mature radiation oncology infrastructure, and reimbursement (Medicare, private insurance). Europe (30% share) follows, with strong public healthcare systems (Germany, France, UK, Italy, Spain) and SRS guidelines (ESTRO, EANS). Asia-Pacific (18% share) is the fastest-growing region (CAGR 9.5%), led by China (rising cancer incidence, government investment in radiotherapy, domestic vendors: CIRC, Masep, Our United, Shanghai United Imaging Healthcare), Japan (aging population, high SRS adoption), and South Korea. Rest of World accounts for remaining share.
Gamma Knife vs. Linac Competition: Gamma Knife (dedicated cranial SRS) maintains superiority for: (a) high accuracy (0.15 mm vs. 0.5–1.0 mm for Linac), (b) steep dose fall-off (better critical structure sparing), (c) single-fraction treatment for multiple metastases (192–201 beams simultaneously). Linac-based SRS advantages: (a) multi-purpose (treats cranial and extracranial), (b) fractionated SRT (2–5 fractions) for larger tumors (>3 cm) or eloquent brain locations, (c) no cobalt decay cost, (d) hypofractionated SBRT for body. A December 2025 survey found that 55% of new SRS installations are Linac-based (vs. 30% Gamma Knife, 15% Proton), but Gamma Knife remains preferred for dedicated cranial centers (high-volume brain metastasis programs).
Hypofractionation and Adaptive Radiotherapy: SRS is increasingly moving from “premium add-on” to standard capability in radiation oncology centers, especially for brain metastases, benign intracranial tumors, vascular malformations, and selected extracranial oligometastatic cases. Hypofractionation (2–5 fractions, 6–10 Gy per fraction) reduces normal tissue toxicity for larger tumors (>3 cm) or tumors near critical structures (optic chiasm, brainstem). Adaptive radiotherapy (daily re-planning based on anatomy changes) is emerging for SBRT (lung, liver, pancreas) where organ motion and tumor shrinkage require plan adaptation. Vendors with adaptive workflows (Elekta Unity MR-Linac, Varian Ethos) have competitive advantage.
Software and Automation as Competitive Battleground: Competition is shifting from standalone hardware differentiation toward software- and service-driven end-to-end solutions: (a) auto-contouring (AI-based target and organ-at-risk segmentation, reducing contouring time from 30–60 minutes to 5–10 minutes), (b) auto-planning (AI-based inverse optimization, reducing planning time from 2–4 hours to 15–30 minutes), (c) online/remote QA (machine learning-based quality assurance, remote dosimetry checks), (d) connectivity and data integration (DICOM, FHIR, oncology information systems), (e) standardized deployment across multi-site networks. A January 2026 analysis found that 60% of SRS purchase decisions are influenced by software and automation capabilities (up from 35% in 2020).
Capital and Operational Barriers: Adoption can still be constrained by: (a) capital budgeting cycles (US$1–5 million for Linac-based SRS, US$3–5 million for Gamma Knife, US$20–50 million for Proton), (b) bunker and radiation shielding requirements (room shielding costs US$200,000–500,000), (c) regulatory compliance (FDA 510(k), CE marking, national regulations), (d) time needed to build and retain experienced physics and therapy teams (medical physicists, radiation therapists, dosimetrists). Vendors offering turnkey solutions (site planning, installation, training, physics commissioning, ongoing service) have competitive advantage.
Competitive Landscape: Key players include Elekta (Sweden, Leksell Gamma Knife, Versa HD Linac, Unity MR-Linac), Varian (US, now part of Siemens Healthineers, TrueBeam, Edge, Halcyon), Accuray (US, Radixact TomoTherapy, CyberKnife robotic SRS), American Radiosurgery (US, non-profit Gamma Knife centers), ZAP Surgical Systems (US, self-shielded SRS system, Zap-X), Akesis (US), China Isotope & Radiation Corporation (CIRC, China, domestic Gamma Knife), Masep Medical (China), Our United (China, domestic Linac and Gamma Knife), and Shanghai United Imaging Healthcare (China, uLinac, uRT). Elekta (Gamma Knife market leader) and Varian (Linac market leader) dominate global SRS market (combined share ~60–70%). Accuray is a smaller but innovative competitor (CyberKnife robotic SRS, Radixact helical TomoTherapy). Chinese domestic vendors (CIRC, Masep, Our United, United Imaging) are gaining share in China market (lower cost, government procurement) but have limited global presence.
Exclusive Industry Observations – From a 30-Year Analyst’s Lens
Observation 1 – The Elekta Gamma Knife Moat: Elekta’s Leksell Gamma Knife (dedicated cranial SRS) has a strong competitive moat: (a) 40+ years of clinical evidence (10,000+ publications), (b) established referral networks (Gamma Knife centers perform 500–2,000 procedures annually), (c) patented collimator design (192–201 sources, 4 mm/8 mm/16 mm collimators), (d) proprietary patient positioning (Leksell stereotactic frame, frameless mask system), (e) installed base (400+ Gamma Knife units globally). However, the high capital cost (US$3–5 million) and cobalt replacement cost (US$200,000–400,000 every 5–7 years) limit adoption to high-volume centers. Elekta’s strategy is to maintain premium pricing and focus on dedicated cranial SRS, not compete head-to-head with Linac-based SRS.
Observation 2 – The Varian Linac Dominance: Varian (now Siemens Healthineers) dominates the Linac-based SRS market (60%+ share) through: (a) TrueBeam and Edge platforms with 10 MV FFF (flattening filter free) mode for high dose rate (up to 2,400 MU/min), (b) micro-MLC (2.5 mm leaf width, 5 mm at isocenter), (c) integrated imaging (cone-beam CT, stereoscopic X-ray, surface guidance), (d) HyperArc (automated non-coplanar SRS planning), (e) installed base (8,000+ Linacs globally, upgrade to SRS-capable). Varian’s strategy is to sell SRS as an upgrade option (US$500,000–1,000,000) to existing Linac customers, driving incremental revenue.
Observation 3 – The China Domestic Vendor Challenge: China has 2,000+ Linacs (mostly imported Varian, Elekta) and 100+ Gamma Knife units (mostly imported Elekta). Chinese domestic vendors (CIRC, Masep, Our United, United Imaging) offer SRS systems at 30–50% lower price than imported systems (US$700,000–1,000,000 vs. US$1.5–2.5 million). Government procurement policies favor domestic vendors (“Buy China” policy). A February 2026 analysis found that 40% of new Linac purchases in China are domestic (up from 15% in 2020), driven by United Imaging (uLinac, uRT) and Our United. For global vendors (Elekta, Varian, Accuray), China remains a growth market but domestic competition intensifies.
Key Market Players
- Elekta (Sweden): Gamma Knife leader, Linac (Versa HD, Unity MR-Linac). Strong in dedicated cranial SRS.
- Varian (Siemens Healthineers, US): Linac leader (TrueBeam, Edge, Halcyon). Strong in multi-purpose SRS/SBRT.
- Accuray (US): CyberKnife (robotic SRS, real-time tracking), Radixact (helical TomoTherapy). Niche but innovative.
- ZAP Surgical (US): Zap-X (self-shielded SRS, no bunker required). New entrant (first US installation 2019).
- Chinese Domestic Vendors (CIRC, Masep, Our United, United Imaging): Low-cost, domestic market focus, gaining share.
Forward-Looking Conclusion (2026–2032 Trajectory)
From 2026 to 2032, the SRS market will be shaped by four forces: Linac-based SRS gaining share (55% to 65%+); hypofractionation and adaptive radiotherapy (2–5 fractions, daily re-planning); software and automation (AI contouring, auto-planning, remote QA); and Asia-Pacific growth (China domestic vendors, rising cancer incidence). The market will maintain 7–8% CAGR, with Linac-based SRS and SBRT segments outperforming Gamma Knife and Proton.
Strategic Recommendations
- For radiation oncology and neurosurgery program directors: For high-volume cranial SRS (brain metastases, benign tumors), consider dedicated Gamma Knife (Elekta) for superior accuracy and throughput (20–30 patients per day). For multi-purpose (cranial + extracranial SBRT), Linac-based SRS (Varian, Elekta, Accuray) is more cost-effective (single platform for conventional radiotherapy, IMRT, VMAT, SRS, SBRT). For pediatric brain tumors or re-irradiation, consider Proton Beam SRS (if available).
- For hospital administrators and capital planners: For new SRS program, total investment includes: (a) system cost (US$1–5 million), (b) bunker shielding (US$200,000–500,000), (c) physics commissioning (US$50,000–100,000), (d) staffing (medical physicist, dosimetrist, radiation therapist, nurse, physician). Reimbursement (US Medicare: US$10,000–15,000 per SRS procedure, commercial insurance: US$20,000–40,000). Break-even volume: 200–300 procedures annually for Linac-based SRS, 300–500 for Gamma Knife.
- For marketing managers at SRS vendors: Differentiate through: (a) targeting accuracy (mm), (b) dose fall-off (mm per 50% dose drop), (c) automation (auto-contouring, auto-planning, auto-QA), (d) multi-modality imaging integration (MRI, PET, cone-beam CT), (e) motion management (respiratory gating, fiducial tracking, surface guidance), (f) treatment delivery speed (minutes per fraction), and (g) service and training (turnkey installation, physics support, remote QA). The academic medical center segment requires advanced research capabilities (MR-Linac, adaptive radiotherapy, radiomics); the community hospital segment requires ease of use, lower cost, and comprehensive service.
- For investors: Monitor cancer incidence trends, reimbursement policy changes (US Medicare, China NHSA), and SRS clinical trial results (local control, survival, toxicity) as key indicators. Publicly traded companies with SRS exposure include Elekta (STO: EKTAb), Varian (part of Siemens Healthineers, ETR: SHL), Accuray (NASDAQ: ARAY). United Imaging (China, private), CIRC (China, private). SRS is a steady-growth (7–8% CAGR), high-margin (30–45% gross) medical device market, with Linac-based SRS and software/automation as key growth drivers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
